In a report released yesterday, Elliot Wilbur from Raymond James reiterated a Buy rating on PolyPid (PYPD), with a price target of $23.00. The company’s shares closed last Wednesday at $9.00, close to its 52-week low of $8.40.
According to TipRanks.com, Wilbur is ranked 0 out of 5 stars with an average return of -3.7% and a 41.7% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Currently, the analyst consensus on PolyPid is a Moderate Buy with an average price target of $23.00.
See today’s analyst top recommended stocks >>
Based on PolyPid’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $7.55 million. In comparison, last year the company had a GAAP net loss of $3.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PolyPid Ltd was incorporated under the laws of Israel and commenced its operations on February 28, 2008. The Company is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company’s proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.
